> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novavax Up 12.1% And Relmada Up 10.7% As Biotech ETF Gains 2.8% Friday, Beating The S&P 500
- URL: https://www.bullished.co/novavax-up-12-1-and-relmada-up-10-7-as-biotech-etf-gains-2-8-friday-beating-the-s-p-500/
- Published: 2026-10-09T19:39:33.000Z
- Updated: 2026-10-09T19:39:33.000Z
- Description: Six of 112 major biotech names led Friday's move, while the sector ETF rose 2.8% against 0.5% for the S&P 500 proxy.
- Author: Matteo Parrino
- Tags: Markets, Industry: Not classified

Six of 112 major biotech stocks rose sharply in Friday's session, led by Novavax, up 12.1%, and Relmada Therapeutics, up 10.7%, according to market data as of 12:00 p.m. ET. The SPDR S&P Biotech ETF, XBI, gained 2.8% in the same session, against 0.5% for SPY, the S&P 500 proxy.

## The six leaders

The six biggest movers averaged a gain of about 9% in Friday trading, as of 12:00 p.m. ET.

Novavax rose 12.1% and Relmada Therapeutics 10.7%. Iovance Biotherapeutics gained 8.7% and Moderna 8.5%. Arcutis Biotherapeutics added 7.9% and Vaxcyte climbed 7.4%.

Fifteen other names in the reading also rose, from Prothena's 6.7% down to ALX Oncology Holdings' 3.4%. Those moves were smaller.

## How the sector compared with the market

XBI's 2.8% gain outpaced SPY's 0.5% by a wide margin in Friday trading.

The move was narrow within the group: the rest of the 112 names did not move sharply higher. No single catalyst has been identified for the rally in the material reviewed.

The reading leaves a simple split: six names led, fifteen followed more modestly, and the remaining names in the group sat out Friday's rally.